Endoscopy 2020; 52(S 01): S19
DOI: 10.1055/s-0040-1704064
ESGE Days 2020 oral presentations
Friday, April 24, 2020 08:30 – 10:30 Blood on the tracks Wicklow Meeting Room 3
© Georg Thieme Verlag KG Stuttgart · New York

COMPLEX ANTITHROMBOTIC THERAPY IN PATIENTS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING: CLINICAL OUTCOMES

S Mashlab
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
P Garcia - Iglesias
2   Hospital Universitari Parc Tauli, Gastroenterology, Sabadell, Spain
,
E Martinez-Bauer
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
A Soria
2   Hospital Universitari Parc Tauli, Gastroenterology, Sabadell, Spain
,
J Vives
2   Hospital Universitari Parc Tauli, Gastroenterology, Sabadell, Spain
,
M Raurich
3   Hospital Universitari Parc Tauli, Documentació Clínica i Arxiu, Sabadell, Spain
,
S Marin
3   Hospital Universitari Parc Tauli, Documentació Clínica i Arxiu, Sabadell, Spain
,
F Junquera
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
V Puig-Divi
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
X Calvet
2   Hospital Universitari Parc Tauli, Gastroenterology, Sabadell, Spain
,
R Campo
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
E Brullet
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
,
A Lira
1   Hospital Universitari Parc Tauli, Endoscopy, Sabadell, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
23 April 2020 (online)

 

Aims Analyze the relationship of CAT (dual treatment: antiplatelet-anticoagulant or antiplatelet-antiplatelet) and the adverse outcomes in patients with acute lower gastrointestinal bleeding (LGB).

Methods International Classification of Diseases, 9th Revision, Clinical Modification codes for admission diagnosis were used to identify retrospectively a cohort of patients with LGB from January 2013 to December 2017 hospitalized in a tertiary care, university-affiliated hospital. The outcomes studied were: A) severe LGB, B) Re-bleeding, C) Transfusion requirements, D) Treatment (endoscopy, interventional radiology or surgery), E) Readmission and F) Death. For discrete variables we tested for significant differences between groups with X2 tests If ≥25 % of cells had expected values less than 5; Fisher exact test was used. P values < 0.05 were considered statistically significant. Differences in outcomes were expressed in odds ratio (OR) with 95% confidence intervals (95%CI).

Results Were identified 417 patients (88.5%) in not CAT group versus 54 (11.5%) in CAT group. Mean age was 76.8 years in CAT group versus 72.6 in not CAT group, 203 (48.7%) were men in not CAT group and 42 (77.8%) in patients using CAT. The most common source bleeding was diverticular 114 (27.3%) in not CAT group and ischemic colitis 13 (24.1%) in CAT group. Outcomes of patients are show in [Table 1.]

Tab. 1

Outcomes of patients admitted for LGB ( With CAT treatment versus without CAT treatment)

With CAT 54(11.5%)

Without CAT 417 (88.5%)

OR (IC95%)

Severe LGB

24 (44.4%)

115(27.8%)

2.1 (1.18-3.75)

Transfusion/Rebleeding

23 (42.6%)/8 (14.3%)

105 (25.2%)/34(8.2%)

2.21(1.23-3.95)/1.96 (0.86-4.49)

Treatment/Readmission

10 (18.5%)/8 (14.3%)

50 (12 %)/12 (2.9%)

1.67 (0.79-3.52)/5.87 (2.28-15.1)

Death

0 (0%)

6 (1.4%)

2.1(1.18-3.75)

Conclusions Patients in CAT have a higher frequency of severe LGB; transfusion and readmission compared to patients without CAT. No difference was found between them for re-bleeding, need for treatment and death.